UPDATE 1-Arseus makes three acquisitions, sees more this year
* Arseus has become consolidator in medical compounding sector
* Price around 16.5 mln euros for three companies
* Combined annual revenue 12 mln, core profit margin 25 pct (Recasts, adds CEO comments, details on consensus)
BRUSSELS, Nov 13 (Reuters) - Belgo-Dutch medical supplies firm Arseus has made three acquisitions in drug compounding and plans to announce more by the end of the year as it seeks to benefit from a growing trend of pharmacists mixing their own medicines.
The firm, which also sells dentist chairs and surgical equipment, said on Tuesday it has made acquisitions in Brazil, Colombia and Scandinavia worth around 16.5 million euros ($21 million) in total.
The firm is the only real global company that supplies ingredients for compounding, meaning it has become the consolidator in the sector.
"There are lots of opportunities and we are involved in numerous processes now, so we hope to announce a little bit more before the end of the year," Chief Executive Ger van Jeveren told Reuters in a telephone interview.
He said the company has 75 million euros in cash that is still available for acquisitions.
Arseus said the three added companies would generate a combined annual revenue of 12 million euros, with a 25 percent core profit margin.
- Separatists take armored vehicles, humiliating Ukraine forces |
- Search resumes for hundreds missing in South Korean ferry disaster |
- Ocean floor search for missing Malaysia plane cut short again
- BofA reports first quarterly loss since 2011 on lofty legal bill
- Wall Street gains on Yellen comments and Yahoo; BofA falls